Thank you, New York Times. Remember just a couple of weeks ago, when The New York Times wrote about how Genentech's (DNA) Avastin was too expensive and the stock got cracked down to $77? I know Roche did. I bet that was the last draw. The dramatic decline in the dollar plus a sentiment that has spawned a thousand articles -- that life-saving drugs cost too much -- gave the Swiss giant a chance to bolster its own anemic pipeline by buying what may be the greatest wonder drug of all time in its $43 billion bid, no doubt the beginning price for what will ultimately be a deal close to $100 a share. (I pushed DNA hard here and on "Mad Money" because I have been a huge believer in Avastin and I'm confident that people will pay anything -- or family members will pay anything -- for the hope of three or four months or more of life, or the chance of beating cancer altogether.)

Just like in 1990, the biotechs -- then led by Amgen (AMGN) -- produced spectacular results as their earnings shined in the face a collapse in the financials.

I bought Gilead (GILD) on Friday for Action Alerts PLUS with the trashing it endured because it spent too much -- consider it the Research In Motion (RIMM) of the group.

Amgen, coincidentally, has been rallying on a better reimbursement environment from the new Medicare bill, an adjunct to DaVita's (DVA) boost.

Don't forget that the whole group is running, including Biogen (BIIB), as the B section of the Journal shows, and Cephalon (CEPH), which seems like nothing but net lately.

Don't forget that the whole group is running, including Biogen (BIIB), as the B section of the Journal shows, and Cephalon (CEPH), which seems like nothing but net lately.